Roselyne Castonguay

USPTO Granted Patents = 33 (Patent Applications = 22)

CIPO Patents = 3 (Patent Applications = 15)

EPO Patents = 11 (Patent Applications = 29)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Malden, MA (US) (2017 - 2024)
Cambridge, MA (US) (2019 - 2024)
Watertown, MA (US) (2019 - 2024)

Company Filing History:

32 out of 167

Acceleron Pharma Inc.

The Brigham and Women's Hospital, Inc.

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421295 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2025-09-23),

2. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),

3. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),

4. 12168683 - Binders of TGFβ-superfamily ligands and uses thereof (2024-12-17),

5. 12103959 - Multispecific binders of TGFBeta-superfamily ligands and uses thereof (2024-10-01),

6. 12054753 - Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers (2024-08-06),

7. 12042524 - Activin type 2 receptor binding proteins methods of making them (2024-07-23),

8. 12024563 - ALK7 antagonists and uses thereof (2024-07-02),

9. 11981738 - ALK7 binding proteins and uses thereof (2024-05-14),

10. 11951156 - Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor (2024-04-09),

11. 11827689 - ALK7:ActRIIB heteromultimers and uses thereof (2023-11-28),

12. 11708414 - ALK7 binding proteins and uses thereof (2023-07-25),

13. 11590201 - Endoglin peptides to treat fibrotic diseases (2023-02-28),

14. 11440949 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2022-09-13),

15. 11279746 - ALK4:ActRIIB heteromultimers and uses thereof (2022-03-22),

Title: The Innovator Extraordinaire: Roselyne Castonguay

Introduction:

Roselyne Castonguay, a visionary inventor hailing from Watertown, MA, has amassed an impressive 27 patents throughout his illustrious career. His groundbreaking work in the field of technology has not only pushed the boundaries of innovation but has also left an indelible mark on the landscape of modern inventions.

Latest Patents:

1. Activin type 2 receptor binding proteins methods of making them: Roselyne's latest patent showcases ActRII-binding proteins, including antibodies that inhibit ActRII activity. These proteins hold tremendous potential for diagnosing and treating various diseases such as muscle wasting, fibrotic conditions, cancer, and more.

2. ALK7 antagonists and uses thereof: Another pioneering patent by Roselyne focuses on ALK7 antagonists, which have shown promise in improving metabolic parameters, treating kidney-associated diseases, and combating cancer.

Career Highlights:

Roselyne Castonguay has made significant contributions while working at esteemed companies like Acceleron Pharma Inc. and Adimab, LLC. His innovative spirit and relentless dedication to advancing medical technology have earned him a reputation as a trailblazer in the industry.

Collaborations:

During his tenure, Roselyne has collaborated with talented individuals such as Ravindra Kumar and Asya Grinberg. Together, they have synergized their expertise to drive forward cutting-edge research and development projects, resulting in groundbreaking inventions.

Conclusion:

In conclusion, Roselyne Castonguay stands as a true pioneer in the world of inventions, with a passion for pushing the boundaries of what is possible and shaping the future of technology. His innovative patents and successful collaborations underscore his profound impact on the field, cementing his legacy as a visionary inventor.

This text is generated by artificial intelligence and may not be accurate.